CliffBio
small molecule

BICALUTAMIDE

BICALUTAMIDE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameBICALUTAMIDE
Active ingredientBICALUTAMIDE
Strength50MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalMay 2010
Marketing statusDISCN

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.